Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures

Mike Enright


For most of the past twenty years, Mr. Enright was the CFO and subsequently President of Ockham Oncology, a CRO focused on Phase I-IV oncology clinical trials. While with Ockham, Mr. Enright helped transform the company from primarily a local biostatistics and data management outsource provider to a full service global CRO with offices from India to the UK and North America. While with Ockham, Mr. Enright was instrumental in making and integrating two acquisitions, as well as spearheading a mezzanine funding raise and ultimately the sale of Ockham to UK-based Chiltern International. Most recently, Mr. Enright has been a fractional C-Suite consultant assisting companies in the life science space with their financial and strategic alternatives.

Mr. Enright previously served on the board of directors of Cornerstone Therapeutics, a specialty pharmaceutical company until their sale in a go private transaction. While with Cornerstone, Mr. Enright served on various committees including the audit, governance and compensation committee.

Mr. Enright has his bachelor’s degree in finance from Villanova University and an MBA from the Kenan Flagler School of Business at the University of North Carolina at Chapel Hill.